It would revolutionise treatment for the condition because it would not have the side effects of many of the current drug-based treatments for the condition
MILLIONS of Britons could be spared the agony of crippling arthritis pain after a major breakthrough by scientists
They have developed a pioneering simple new technique to generate cells which can go on to re-grow damaged cartilage and even bone.
The process offers major hope for people suffering in daily pain from the degenerative joint condition.
It paves the way for a quick treatment – possible as a single injection of the stem cells – directly into the effected joint to end the agony.
At least 8.5 million Britons suffer from osteoarthritis which is caused by wear and tear on joints where the cartilage that cushions movement is worn away.
Bones then come into contact with each other and the friction makes joints swollen and extremely painful.
Now, researchers from the University of Texas Health Science Centre in the US, have used a combination of small molecules to generate mouse cells that can form bone and cartilage.
They say the new method could allow them to re-grow broken bones and mend cartilage damage to back discs and joints.
It would revolutionise treatment for the condition because it would not have the side effects of many of the current drug-based treatments for the condition.
The research team, led by Dr Naoki Nakayama, created special stem cells known as pluripotent stem cells from mouse embryos.
This type of stem cell has the ability to become any cell type in the body.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Are You Getting Enough Vitamin K?on April 9, 2021 at 12:54 pm
Now, a growing body of research suggests that getting adequate amounts can help ward off heart disease, cognitive problems, osteoarthritis and physical disability, making it especially important to ...
- Coronal and axial alignment relationship in Caucasian patients with osteoarthritis of the kneeon April 9, 2021 at 10:54 am
In the present study, we investigated the relationship among the coronal alignment and the rotational profile of the lower extremities in the Caucasian population with end-stage knee osteoarthritis.
- Drugs for Osteoarthritis Pain Market Boosting the Growth Worldwide: Market Dynamics and Trends, Efficiencies Forecast 2027on April 9, 2021 at 1:56 am
Apr 09, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Drugs for Osteoarthritis Pain Market” Report 2021 covers strong research on global ...
- Clinical Studies Find sam® Developed by ZetrOZ Systems Effectively Treats Osteoarthritison April 6, 2021 at 7:23 am
“It’s a win-win for everyone involved.” In 2020, researchers examined the use of sustained acoustic medicine and ultrasound gel to treat 32 patients with moderate to severe pain from knee ...
- Spine Osteoarthritis Pain Drug Market Size (5.5% CAGR) 2020 Driving Factors, Industry Growth, Key Vendors and Forecasts to 2025on April 6, 2021 at 5:38 am
Apr 06, 2021 (Market Insight Reports) -- Selbyville, Delaware Market Study Report LLC adds new research on Spine Osteoarthritis Pain Drug market, which is a detailed analysis of this business space ...
- BCM-95® Curcumin Powerful Anti-Inflammatory for Knee Osteoarthritison April 6, 2021 at 4:00 am
Results were published in the journal Biomed Central BMC. For the study, 193 patients diagnosed with osteoarthritis of the knee were randomized to receive either turmeric extract (BCM-95®) as a ...
- New Invention Stops or Delays the Progression of Osteoarthritis of the Kneeon April 1, 2021 at 8:28 am
Stock quotes by finanzen.net NEW YORK, April 1, 2021 /PRNewswire/ -- New York Bone & Joint Specialists is at the forefront of orthopedic technology, with an exciting invention focused on preventing ...
- Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issueson April 1, 2021 at 6:57 am
Ampion™, in osteoarthritis of the knee (OAK), but it has recently revealed early positive results in its AP-014 Phase I clinical trial using inhaled AmpionTM to treat COVID-19 respiratory distress.
- Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?on March 31, 2021 at 8:31 am
Pfizer ( NYSE:PFE) and Eli Lilly ( NYSE:LLY) have worked together for years on the development of an osteoarthritis pain drug, tanezumab. In this Motley Fool Live video recorded on March 24, 2021, ...
- Opinion: How New Zealand's healthcare system is failing people with osteoarthritison March 31, 2021 at 12:26 am
OPINION: Osteoarthritis is the most common form of arthritis, affecting almost 650 million people over the age of 40 worldwide. In New Zealand, around one in eight adults have osteoarthritis, but it ...
via Bing News